ACHN stock has been on a roll for two days straight after Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced positive updates from the Phase 1 study of its product ACH-5228, an experimental oral factor D inhibitor.
ACHN Stock Goes WildThe announcement was made on Monday, and soon after, the stock climbed by as much as 16.50% to close the session at $2.77. However, the climb yesterday was not a one-off, and the stock regained its momentum on Tuesday morning, as it soared another 33% once the markets opened today.
That being said, some may wonder ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.